- Home
- MDGL vs ALLE Comparison
MDGL vs ALLE Comparison
Compare MDGL & ALLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | ALLE |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 11.7B |
| IPO Year | 2005 | 2013 |
Fundamental Metrics
Financial Performance| Metric | MDGL | ALLE |
|---|---|---|
| Price | $542.61 | $155.56 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 8 |
| Target Price | ★ $674.45 | $167.13 |
| AVG Volume (30 Days) | 246.5K | ★ 1.3M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 1.60% |
| EPS Growth | N/A | ★ 9.09 |
| EPS | N/A | ★ 3.74 |
| Revenue | ★ $180,133,000.00 | N/A |
| Revenue This Year | $58.39 | $8.47 |
| Revenue Next Year | $48.55 | $4.58 |
| P/E Ratio | ★ N/A | $41.46 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $393.61 | $125.00 |
| 52 Week High | $615.00 | $183.11 |
Technical Indicators
Market Signals| Indicator | MDGL | ALLE |
|---|---|---|
| Relative Strength Index (RSI) | 55.57 | 44.79 |
| Support Level | $529.02 | $139.95 |
| Resistance Level | $545.13 | $166.96 |
| Average True Range (ATR) | 17.76 | 3.70 |
| MACD | 2.63 | -1.80 |
| Stochastic Oscillator | 78.60 | 23.64 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About ALLE Allegion plc
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2024, Allegion generated over 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy, Switzerland-based Dormakaba, and US-based Fortune Brands Innovations.